Table 3. .
Factors Associated With Liver Fibrosis Among HIV-Infected Male Patients Attending AIDC and GPC Care Clinics in Urban and Rural Uganda (2015–2017)
| Urban Clinic | Rural Clinic | |||
|---|---|---|---|---|
| Explanatory Variable | Adjusted Analysis | P Value | Adjusted Analysis | P Value |
| OR (95% CI) | OR (95% CI) | |||
| Age (10-y increase) | 1.3 (1.1–1.6) | .008 | 1.0 (0.8–1.3) | .878 |
| Ever used alcohol | 0.6 (0.4–0.9) | .033 | 0.7 (0.4–1.2) | .193 |
| Ever used tobacco | 1.7 (1.1–2.7) | .022 | 1.7 (1.0–2.7) | .035 |
| Ever used herbal medicine | 1.1 (0.7–1.7) | .754 | 1.1 (0.6–2.0) | .746 |
| Hepatitis B surface antigen test positive | 1.1 (0.6–1.9) | .728 | 1.4 (0.7–2.5) | .309 |
| Hepatitis C antibody positive | 3.1 (1.1–8.6) | .028 | 3.5 (1.1–11.0) | .030 |
| On ART | 0.8 (0.9–7.2) | .840 | 0.9 (0.1–8.5) | .936 |
| Detectable HIV viral load (≥1000 copies/mL) | 2.3 (1.2–4.6) | .002 | 1.8 (0.9–3.7) | .101 |
| Elevated liver transaminasesa | 2.2 (1.3–3.7) | .002 | 1.4 (0.7–2.5) | .314 |
Abbreviations: AIDC, Adult Infectious Diseases Clinic; ART, antiretroviral therapy; GPC, General Population Clinic; OR, odds ratio.
aAIDS Clinical Trials Group classification.